Transdermal Drug Delivery Systems Market Analysis – Growth & Opportunities
The global transdermal drug delivery system market size was $52,476.50 million in 2020, and is projected to reach $87,322.40 million by 2030, growing at a CAGR of 4.9%
According to the recent report released by Allied Market Research, the global transdermal drug delivery systems market size is predicted to grow to $87,322.40 million by 2030, having gained a value of $52,476.50 million in 2020, showcasing a considerable CAGR of 4.9% from 2021 to 2030. This market report provides a comprehensive analysis of leading investment pockets, top market segments, market dynamics, market size and forecasts, competitive analysis, and regional analysis. It is an essential resource for the stakeholders, and leading market players to strategically plan and enhance their competitive advantage.
Recent Development in Transdermal Drug Delivery Systems Market
- In September, 2022, Corium, Inc., a fully-integrated biopharmaceutical company, announced the launch of ADLARITY (donepezil transdermal system) in the U.S. for the treatment of patients with mild, moderate, or severe dementia of the Alzheimer's type.
- In November, 2023, DifGen Pharmaceuticals LLC announced the launch of its second complex Transdermal product, generic Buprenorphine Transdermal System (Gx to Butrans(R)) in the US market.
The global transdermal drug delivery systems market is categorized into various segments based on type, application, and region. It is offered in both tabular and graphical form, permitting an individual or a commercial organization to benefit perception into the highly profitable and swiftly expanding segments.
By type, the passive segment accounted for the major market share in 2020, acquiring nearly three-fifths of the global transdermal drug delivery systems market revenue. On the other hand, the active segment would cite the fastest CAGR of 5.6% throughout the forecast period.
By application, the analgesics segment garnered the major market share in 2020, holding around one-third of the global transdermal drug delivery systems market revenue. The motion sickness segment, simultaneously, would display the fastest CAGR of 6.3% throughout the forecast period.
By region, the market across North America dominates the largest share in 2020, contributing to more than two-fifths of the global transdermal drug delivery systems market. However, the market across the Asia-Pacific region would exhibit the fastest CAGR of 6.1% throughout the forecast period. The Europe and LAMEA provinces are also studied in the report.
The report also provides an in-depth analysis of the leading players in the global transdermal drug delivery systems market including Novartis AG, Hisamitsu Pharmaceutical Co. Inc., Viatris Inc., Boehringer Ingelheim GmbH, Altaris, GlaxoSmithKline Plc., Bayer AG, Purdue Pharma L.P., Johnson & Johnson, and Endo International Plc.
Comprehensive Healthcare Industry Research Studies: -
Endoscopy Fluid Management Market - Global Opportunity Analysis and Industry Forecast, 2022–2032
Prosthetics Market - Global Opportunity Analysis and Industry Forecast, 2022–2032
Neonatal Ventilator Market - Global Opportunity Analysis and Industry Forecast, 2022–2032